Compare NGVT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVT | AUPH |
|---|---|---|
| Founded | 1964 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2015 | 2014 |
| Metric | NGVT | AUPH |
|---|---|---|
| Price | $76.61 | $16.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $72.50 | $17.25 |
| AVG Volume (30 Days) | 262.1K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.10 | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $1,167,600,000.00 | $283,055,000.00 |
| Revenue This Year | $3.63 | $17.54 |
| Revenue Next Year | $0.50 | $15.74 |
| P/E Ratio | ★ N/A | $7.75 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $30.19 | $7.29 |
| 52 Week High | $77.46 | $16.54 |
| Indicator | NGVT | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 68.42 | 65.87 |
| Support Level | $63.60 | $14.56 |
| Resistance Level | $77.23 | $16.28 |
| Average True Range (ATR) | 1.97 | 0.53 |
| MACD | 0.75 | 0.14 |
| Stochastic Oscillator | 94.58 | 87.56 |
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.